Back to the articles
Promising North American Clinical Study on the Use of SIMBA Capsule to Detect a Dietary Intervention in the Small Intestine
Lallemand Health Solutions and Nimble Science are proud to officially kick-off the first North American clinical study of Nimble’ Small Intestine Microbiome Aspiration (SIMBA) Capsule, led by Dr. Christopher N. Andrews of the Division of Gastroenterology at the University of Calgary.
Nimble Science ’s SIMBA ingestible capsule passively samples the small intestine and autonomously transits the gastrointestinal tract.
“This particular capsule can be used to provide a novel solution for research of the gut microbiota, investigating various health conditions etiology, impact of interventions specifically within the small intestine and new biomarker identification, hence leading to advances in personalized medicine and nutrition. Lallemand Health Solutions is proud to support this innovative non-invasive technology to improve the understanding of probiotic intervention”, said Sara Caballero, Clinical Research Specialist at the Rosell Institute for Microbiome and probiotics, by Lallemand.
The study titled, “Use of the Small Intestine Microbiome Aspiration (SIMBA) Capsule to detect Dietary Intervention in the Small Intestine” will recruit 20 participants and is expected to be completed within the first quarter of 2021. The study is being conducted under Investigational Testing authorization from Health Canada (#318739) and University of Calgary Conjoint Research Ethics Board (REB20-1211). More details on the study can be found at https://clinicaltrials.gov/ct2/show/NCT04489329
Nimble Science, a medical device company located in Calgary, Canada, aims to develop a scalable, passive access to the gut microbiome to enable broad innovation for the detection and treatment of human disease. Throughout 2021, Nimble Science, will begin to engage with a full range of partners to demonstrate the potential of the SIMBA capsule to drive further innovative initiatives.
Lallemand Health Solutions is a privately-owned Canadian company that researches, manufactures, and markets probiotic bacteria and yeast to nutritional and pharmaceutical companies that sell to the consumer and is a global leader of the probiotic industry with 600 formulas distributed in more than 60 countries. Lallemand Health Solutions is a research driven company and has an interest in innovative tools to evaluate the beneficial effect of probiotics in the human body and to understand the mechanisms of action of these microorganisms. www.lallemand-health-solutions.com
The Rosell® Institute for Microbiome and Probiotics by Lallemand, Lallemand Health Solutions’ research and development center located at the National Research Council of Canada in Montreal, develops partnerships with key scientific experts in order to study the human microbiome and how probiotic supplements can be used as a means to improve or maintain health in specific populations or health segments. The research team has issued over 330 publications including 160 clinical studies. www.rosellinstitutelallemand.com
Nimble Science: Joseph (Gang) Wang, CEO firstname.lastname@example.org
Lallemand Health Solutions: Marilou Luneau, Content Manager email@example.com